Replies to post #10900 on GTC Biotherapeutics (fka GTCB)

[Biowatch]

>>if “squeezing” were to hurt the prospective partner financially, it could backfire on the squeezer by lessening the productivity of the eventual partnership.<<

Yes, it's in everyone's best interest that the small company has sufficient funds to accomplish the goal efficiently and without incentive to cut corners. As long as reasonable oversight makes sure money isn't wasted (good idea regardless), short changing necessary work is like cutting off your nose to spite your face.

[waynebio]

<Such a negotiating tactic would incur a large risk of losing the deal altogether to another suitor.>

Perhaps the prospective partner is not worried about losing the deal by squeezing GTCB because there is only one prospective partner. The last 6 months has proven that there are not multiple partners stumbling over each other to make a generous deal with GTCB. It is not like GTCB is selling some high demand commodity here.

<Moreover, if “squeezing” were to hurt the prospective partner financially, it could backfire on the squeezer by lessening the productivity of the eventual partnership.>

Perhaps the partner would like to play the squeeze until GTCB gives up and agrees to a take over.